Lung Cancer

Genetic Predisposition to Lung Cancer May Be Greater in Women Than in Men

By

Vicki Moore, PhD

Publish Date September 20, 2023

New research suggests that genetic susceptibility to lung cancer is greater in women, and a family history of cancer predicts lung cancer risk.

Iruplinalkib Outperforms Crizotinib in ALK+, Advanced NSCLC

By

Aaron Tallent

Publish Date September 20, 2023

Iruplinalkib, a novel ALK inhibitor, was more effective than crizotinib in a phase 3 trial of patients with advanced, ALK-positive non-small cell lung cancer.

Incidence of Lung Cancer Subtypes Varies by Region

By

Alexandra Della Pia, PharmD, MBA, BCOP

Publish Date September 19, 2023

Incidence rates of lung cancer subtypes vary across global regions, data suggest.

Multidisciplinary Approach to Immune-Related AE Management in NSCLC Improves Outcomes 

By

Megan Garlapow, PhD

Publish Date September 18, 2023

Researchers investigated the effects of multidisciplinary clinical management of IMDC in patients with NSCLC undergoing treatment with immune checkpoint inhibitors.

Adding Ipilimumab to Nivolumab Doesn’t Provide Meaningful Benefit, Researchers Say

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date September 18, 2023

Adding ipilimumab to treatment with nivolumab does not provide a clinically meaningful benefit in patients with certain cancers, a meta-analysis suggests.

Lung Cancer Clinical Trials

Clinical Trial: Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer

Clinical Trial: Improving Management of Breathlessness in Patients With Lung Cancer

Clinical Trial: Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker

Clinical Trial: Lung Cancer Biomarkers and Screening (NYULCBC)

Clinical Trial: Proton Therapy for Stage I Non-Small Cell Lung Cancer (LU03)